Log In
BCIQ
Print this Print this
 

Voraxaze, glucarpidase

  Manage Alerts
Collapse Summary General Information
Company BTG plc
DescriptionRecombinant enzyme that breaks down methotrexate in blood
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationPoisoning
Indication DetailsAdjunct for methotrexate (MTX) toxicity; Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function
Regulatory Designation U.S. - Orphan Drug (Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function);
U.S. - Priority Review (Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function);
EU - Orphan Drug (Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function)
PartnerOhara Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/12/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today